Streetwise Articles By Production Types

EU Biopharma Co. Makes $247M Bid for US Oncology Co.

Streetwise Reports (06/27/2022)

Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share.

Tags: Biotechnology / Pharmaceuticals

Approval Likely of New Gel for Skin Condition, Analyst Says

Research Report

(06/27/2022)

The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Gene Therapy Co. Releases Data From Huntington's Study

Streetwise Reports (06/23/2022)

Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial

Streetwise Reports (06/22/2022)

Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.

Tags: Biotechnology / Pharmaceuticals

New Positive Data Seem to Support Drug Label Expansion

Research Report

(06/21/2022)

Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.

Tags: Biotechnology / Pharmaceuticals

Results of Dermatitis Clinical Trial Due This Summer

Research Report

(06/21/2022)

Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

New Drug for Heart Failure on Path to Approval, Analyst Says

Research Report

(06/20/2022)

The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

NFL Player Teams With Biopharma Co. to Help SCD Patients

Streetwise Reports (06/17/2022)

Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease.

Tags: Biotechnology / Pharmaceuticals

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Research Report

(06/16/2022)

The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Advances 3 New Clinical Stage Assets

Research Report

(06/16/2022)

Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results

Streetwise Reports (06/13/2022)

Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Research Report

(06/10/2022)

Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.

Tags: Biotechnology / Pharmaceuticals

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Research Report

(06/10/2022)

The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results

Streetwise Reports (06/10/2022)

Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder.

Tags: Biotechnology / Pharmaceuticals

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Research Report

(06/09/2022)

Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success

Contributed Opinion

Tim Weintraut (06/08/2022)

After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough.

Tags: Special SituationsRegenerative MedicineBiotechnology / Pharmaceuticals

Biopharma Co. Meets Primary Endpoints in ARDS Trial

Streetwise Reports (06/08/2022)

MediciNova Inc. shares traded 9% higher after the company released top-line data from its Phase 2 study of MN-166 (ibudilast) in hospitalized COVID-19 patients deemed to be at elevated risk for acute respiratory distress syndrome. In the study, MN-166 demonstrated significant decreases in respiratory failure.

Tags: Biotechnology / Pharmaceuticals

FDA Approves Co.'s New Medical Grade Air Hygiene Device

Streetwise Reports (06/07/2022)

Shares of AeroClean Technologies Inc. traded 150% higher after the company reported it received 510k clearance from the U.S. FDA for its Pūrgo™ medical-grade indoor air purification technology that uses UV-C LEDs to eradicate airborne bacteria, fungi, and viruses, including COVID-19.

Tags: TechnologyHealthcare ServicesBiotechnology / Pharmaceuticals

Approved Drug Shows Promise in Follicular Lymphoma

Research Report

(06/06/2022)

Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

FDA Approval of Drug Could Be on the Way

Research Report

(06/03/2022)

"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection.

Tags: Biotechnology / Pharmaceuticals

Bristol Myers to Buy Precision Oncology Co.

Streetwise Reports (06/03/2022)

Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share.

Tags: Biotechnology / Pharmaceuticals

Precision Oncology Co. Signs $1.325B Licensing Deal

Streetwise Reports (06/02/2022)

Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved.

Tags: Biotechnology / Pharmaceuticals

Important Data for COVID Drug Candidate Due This Month

Research Report

(06/02/2022)

The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Cancer Patients Have Partial Response With Drug

Research Report

(05/28/2022)

The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Cancer Targeting Drug Better Tolerated Than Others

Research Report

(05/27/2022)

A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report.

Tags: Biotechnology / Pharmaceuticals

The Life Sciences Report

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

EU Biopharma Co. Makes $247M Bid for US Oncology Co.

Approval Likely of New Gel for Skin Condition, Analyst Says

Gene Therapy Co. Releases Data From Huntington's Study

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial

New Positive Data Seem to Support Drug Label Expansion

Results of Dermatitis Clinical Trial Due This Summer

New Drug for Heart Failure on Path to Approval, Analyst Says

NFL Player Teams With Biopharma Co. to Help SCD Patients

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Biotech Co. Advances 3 New Clinical Stage Assets

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success

Biopharma Co. Meets Primary Endpoints in ARDS Trial

FDA Approves Co.'s New Medical Grade Air Hygiene Device

Approved Drug Shows Promise in Follicular Lymphoma

FDA Approval of Drug Could Be on the Way

Bristol Myers to Buy Precision Oncology Co.

Precision Oncology Co. Signs $1.325B Licensing Deal

Important Data for COVID Drug Candidate Due This Month

Cancer Patients Have Partial Response With Drug

Cancer Targeting Drug Better Tolerated Than Others

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

More Experts